title: Long-term follow-up and prognostic factors for advanced thymic carcinoma.
abstract: The aim of this study was to evaluate the long-term survival outcomes in patients with advanced thymic carcinoma and identify prognostic factors influencing the survival. We retrospectively analyzed 90 consecutive patients with pathologically confirmed advanced thymic carcinoma (Masaoka III and IV) in our institute, from December 2000 to 2012. Age, sex, clinical characteristics, laboratory findings, Masaoka and tumor node metastasis staging, pathologic grade, and treatment modalities were analyzed to identify prognostic factors associated with the progress-free survival (PFS) and the overall survival (OS) rates. Statistical analysis was conducted using SPSS, version 19.0 (SPSS, Inc, Chicago, IL). A total of 73 (81.1%) male and 17 (18.9%) female patients participated in the study. The median follow-up time was 75 months (range, 20-158 months). The 5-year PFS and OS rates were 23.6% (95% confidence interval [CI], 14.6%-33.8%) and 35.7% (95% CI, 25.1%-46.4%), respectively. The multivariate Cox regression model analysis showed that factors improving the PFS were the normal lactate dehydrogenase (LDH) level (P<0.001), Masaoka III stage (P=0.028), and radiotherapy (RT) (P<0.001). The LDH (P<0.001), T stage (P<0.001), and the pathologic grade (P=0.047) were independently prognostic of OS. Long-term follow-up of the advanced thymic carcinoma showed poor outcomes of PFS and OS. LDH, Masaoka stage, and RT affected the PFS, and LDH, T stage, and pathologic grade seemed to affect the OS. Establishing a better staging system for predicting outcomes would be warranted.
authors.affiliation: From the Department of Radiation Oncology (JW, HC, LS, SQ, QN, BZ, JW, JP, JL), Teaching Hospital of Fujian Medical University, Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fujian Provincial Cancer Hospital, Fuzhou, China.
authors.forename: Jun-Xin
authors.initials: JX
authors.lastname: Wu
authors.forename: Hui-Qin
authors.initials: HQ
authors.lastname: Chen
authors.forename: Ling-Dong
authors.initials: LD
authors.lastname: Shao
authors.forename: Su-Fang
authors.initials: SF
authors.lastname: Qiu
authors.forename: Qian-Yu
authors.initials: QY
authors.lastname: Ni
authors.forename: Bu-Hong
authors.initials: BH
authors.lastname: Zheng
authors.forename: Jie-Zhong
authors.initials: JZ
authors.lastname: Wang
authors.forename: Jian-Ji
authors.initials: JJ
authors.lastname: Pan
authors.forename: Jin-Luan
authors.initials: JL
authors.lastname: Li
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002681:China / Q000453:epidemiology; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate / Q000639:trends; D013953:Thymus Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D013997:Time Factors; D055815:Young Adult